95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1535235
This article is part of the Research Topic Current Trends and Future Prospects in the Use of Immunotherapy in Ovarian Cancer View all 6 articles
Ovarian Cancer Targeted Therapy: Current Landscape and Future Challenges
Provisionally accepted- 1 Yanbian University, Yanji, China
- 2 Yanbian University Hospital, Yanji, Jilin Province, China
- 3 School of Medicine, Yanbian University, Yanji, Jilin Province, China
- 4 Jilin provincial cancer hospital, Jilin, China
Ovarian cancer is one of the deadliest malignancies in women and remains the leading cause of death from gynecological cancers worldwide. The standard treatment typically involves tumor-reducing surgery and cytotoxic chemotherapy; however, many patients are unable to tolerate the side effects of these treatments or experience recurrence due to significant drug resistance, which limits the overall clinical benefits. Consequently, there is a pressing need for novel therapeutic strategies. In recent years, Targeted therapies, including anti-angiogenic drugs, PARP inhibitors, and immune checkpoint inhibitors, have revolutionized ovarian cancer treatment. Additionally, drug targeting and therapeutic efficacy have been substantially enhanced through carrier technologies and conjugation strategies, such as antibody-drug conjugates, polymer-drug conjugates, and dual-targeted nanomedicines. These innovative strategies aim to selectively target ovarian cancer cells, overcome drug resistance, and reduce systemic toxicity, thus achieving optimal therapeutic outcomes. This review aims to critically evaluate the progress and challenges in ovarian cancer targeted therapy and propose future research directions to improve clinical outcomes efforts toward providing more effective and personalized treatment options for ovarian cancer patients.
Keywords: ovarian cancer, targeted therapy, combination therapy, personalized medicine, Adverse Reactions
Received: 27 Nov 2024; Accepted: 03 Apr 2025.
Copyright: © 2025 Wang, Sun, Wang and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Changhao Jin, Yanbian University Hospital, Yanji, Jilin Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.